New hepatitis b drug shows early promise in small trial
NCT ID NCT07515209
First seen Apr 11, 2026 · Last updated Jun 16, 2026 · Updated 10 times
Summary
This early-stage study tested a new medicine called HH-006 in 36 adults with chronic hepatitis B who had not been treated before. The main goal was to check if the drug is safe and how the body processes it. Participants received either the drug or a placebo as a shot once a week for five weeks, and were monitored for 24 weeks. The study is complete, but results are not yet reported.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B VIRUS INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
NanFang Hospital of Southern Medical University
Guangzhou, Guangdong, 510000, China
-
The Affiliated Panyu Central Hospital of Guangzhou Medical University
Guangzhou, Guangdong, 510000, China
-
The Eighth Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, 510000, China
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.